The company recycled approximately 100 kilograms of textile waste, undertook plantation activities, and encouraged employees to adopt environmentally responsible practices
Chennai based Bioneemtec India has received support from Technology Development Board for commercializing indigenous green chemistry technologies to produce critical pharmaceutical ingredients
The move signals a major expansion in access to next-generation weight-loss therapies
Regulatory clearance strengthens company’s global footprint and expands access to the Australian animal healthcare market
DCGI-approved semaglutide syringes for diabetes and obesity expand treatment choices and improve affordability
At the center of the project is a new cosmetics line developed through collaboration between industry and medicine
The transaction includes an upfront payment of $1.55 billion, along with up to $1.1 billion in regulatory and commercial milestone payments
First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept
This facility plays an important role in Granules’ global manufacturing and supply network
Accreditations for Bhayla manufacturing site strengthen the company’s global quality credentials and support expansion of its hormone portfolio into regulated international markets
Acquisition provides direct access to the Dutch healthcare market, enhancing Marksans’ sales, distribution and market-access capabilities across regulated European markets
The collaboration introduces a flexible, end-to-end CDx framework designed to adapt to shifting regulatory environments
CEPI will commit up to US $50 million to fund preclinical research and Phase 1 clinical trials of Moderna’s mRNA-based vaccine candidate
Fertility platform launches flagship clinic with advanced IVF tech
While oncology contributed Rs. 16,100.9 million to remain company's largest therapy area, the key highlight was receipt of 11 new regulatory approvals for medicines and indications
The aflibercept biosimilar, referencing Eylea, becomes the company’s fifth directly commercialized biosimilar in Europe, expanding access to ophthalmology treatments
This alliance, covering up to 12 antibody drugs, highlights the growing trend of large-scale collaborations between Chinese biotech firms and global pharmaceutical giants
This certification confirms that the facility complies with Good Manufacturing Practice requirements as referred in the EC Directive
Subscribe To Our Newsletter & Stay Updated
